Skip to main content

Table 2 Treatment used and changes in cardiovascular risk profiles in all patients, dieters versus nondieters, and users of methotrexate versus nonusers

From: Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study

 

All patients (n = 22)

Dieters (n = 15)

Nondieters (n = 7)

Methotrexate (n = 14)

No methotrexate (n = 8)

Treatment used

   Pulsed methylprednisolone (mg)

200 (160 to 360)

200 (160 to 230)

200 (140 to 730)

200 (160 to 360)

200 (120 to 730)

   Chloroquine (n [%])

15 (68)

12 (80)

3 (43)

10 (71)

5 (63)

   Methotrexate (n [%])

14 (64)

10 (67)

4 (57)

14 (100)

0 (0)

   Minocyclin (n [%])

9 (41)

7 (47)

2 (29)

7 (50)

2 (25)

   Azathioprine (n [%])

2 (9)

0 (0)

2 (29)

0 (0)

2 (25)

   Nonmethotrexate DMARD per patient (n)

1 (1 to 2)

1 (1 to 2)

1 (1 to 1)

2 (1 to 2)

1 (1 to 2)

Changes in cardiovascular risk

   Weight (kg)

-4 (-6.5 to +0)

-4.6 (-8.6 to -4)

0 (0 to 0.8)

-3.4 (0 to 8.6)

-4 (-6.2 to 0)

   C-reactive protein (mg/l)

-14 (-36 to -6)*

-12 (-36 to -5)

-19 (-35 to -13)

-27 (-83 to -6)

-10 (-13 to -3)***

   Insulin (μU/ml)

-4.5 (-8.8 to -2.5)*

-3.4 (-7.9 to -1.5)

-6.4 (-11.7 to -2.6)

-4.5 (-10.2 to -2.9)

-4.5 (-6.4 to -1.5)

   Glucose (mmol/l)

-0.5 (-0.8 to -0.3)

-0.5 (-0.9 to -0.3)

-0.4 (-0.8 to -0.1)

-0.5 (-1.8 to -0.3)

-0.5 (-0.8 to +0.1)

   HOMA (μU . mmol/ml . l)

-0.95 (-1.49 to -0.50)*

-0.89 (-2.20 to -0.76)

-1.45 (-2.92 to +0.82)

-1.08 (-2.99 to -0.85)

-0.87 (-0.20 to -0.49)

   QUICKI

0.023 (0.014 to 0.049)*

0.021 (0.009 to 0.042)

0.035 (0.023 to 0.046)

0.026 (0.042 to 0.015)

0.022 (0.045 to 0.007)

   Total cholesterol (mmol/l)

-0.05 (-0.9 to +0.5)

-0.6 (-1.2 to 0.0)

0.8 (0.2 to 0.9)*

0.0 (-0.5 to +0.7)

-0.35 (-1.7 to +0.9)

   LDL-cholesterol (mmol/l)

-0.15 (-0.6 to +0.3)

-0.3 (-0.8 to +0.2)

0.3 (0.0 to 0.9)**

-0.15 (-0.4 to -0.2)

-0.05 (-1.5 to -0.8)

   HDL-cholesterol (mmol/l)

0.15 (0 to 0.20)

0.20 (0.02 to 0.21)

0.10 (0.00 to 0.51)

0.20 (0.11 to 0.21)

0.06 (-0.11 to +0.50)

   Triglycerides(mmol/l)

-0.35 (-1.1 to -0.1)

-0.51 (-0.4 to -0.2)

-0.21 (-0.4 to +0.2)

-0.47 (-1.0 to -0.1)

-0.22 (-0.3 to +0.1)

Time between assessments (months)

3 (2.5 to 3)

3 (2.5 to 3)

3 (2 to 3)

3 (2.5 to 3)

3 (2 to 3)

  1. Results expressed as median (interquartile range). In the second column, the significance for changes in cardiovascular risk was analyzed. Nondieters were compared with dieters, and nonusers of methotrexate with users in the other columns. *P < 0.006, **P = 0.015, ***P = 0.04. DMARD, disease-modifying antirheumatic drugs; HDL, high-density lipoprotein; HOMA, Homeostatis Model Assessment for Insulin Resistance; LDL, low-density lipoprotein; QUICKI, Quantitative Insulin Sensitivity Check Index.